Abstract
PSA testing was introduced and rapidly accepted by physicians despite the lack of evidence from randomized trials that early detection and treatment reduce prostate cancer mortality. In the absence of randomized trials, incidence and mortality trends after the introduction of a screening test can provide useful evidence with respect to the benefits of screening. If the test has benefit, one would expect that cancer mortality reductions would be greater in areas where the screening test had high penetration in the population compared with those areas with lower penetration. Cervical cancer screening programs are, in part, supported by the inverse relationship between disease-specific mortality and the prevalence of screening. 1 Laara E. Day N.E. Hakama M. Trends in mortality from cervical cancer in the Nordic countries association with organised screening programs. Lancet. 1987; 1: 1247-1249 Abstract Scopus (559) Google Scholar Are similar convincing data available to support PSA screening?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
